Table 1 Baseline characteristics
WG patientsHealthy controls
Non-vaccinated n  =  23Vaccinated n  =  29Vaccinated n  =  49
Sex, men (%)14 (61%)23 (47%)21 (43%)
Age in years, mean (range)62 (42–88)57 (27–87)47 (25–63)***
Influenza vaccination in previous year (%)13 (57%)32 (65%)4 (8%)***
No immunosuppressives (%)15 (65%)23 (47%)
Prednisone3 (13%)16 (33%)
    Range, in users (mg/day)5–152.5–12.5
Azathioprine5 (22%)19 (39%)
    Range, in users (mg/day)21.4*–15035.7*–150
Other immunosuppressive drugs3† (13%)2‡ (4%)
CRP, median (range)6 (1–43)4 (1–110)nd
  • *Three times 50 mg per week and five times 50 mg per week, respectively. †Three non-vaccinated patients used mycophenolate mofetil (500 mg/day; 1000 mg/day; 2000 mg/day). ‡One vaccinated patient used cyclophosphamide (25 mg/day) and one vaccinated patient used ciclosporine (150 mg/day). ***p<0.001 (healthy controls versus vaccinated WG patients). CRP, C-reactive protein; nd, not determined; WG, Wegener’s granulomatosis.